Summary The effects of cimetidine and indomethacin on the growth of dimethylhydrazine induced or transplanted intestinal tumours in the rat have been studied. Cimetidine is a histamine type 2 receptor antagonist and indomethacin is an inhibitor of prostaglandin synthesis. Two models of rat intestinal tumours were used: a colon carcinoma line transplantable in syngeneic animals and intestinal tumours induced by dimethylhydrazine treatment of Sprague-Dawley rats. Cimetidine and indomethacin were given in drinking water, alone or in combination. Cimetidine had no effect on the growth of transplanted colon cancer but significantly increased the incidence of chemically-induced tumours, with a tendency toward more invasive and metastatic tumours than in the control animals. Indomethacin did not significantly modify the incidence or other characteristics of the tumours in any of the models. This result is at variance with a protective effect of indomethacin on chemically-induced rat colon cancer previously reported by others.
In spite of numerous attempts, treatment of advanced or residual colorectal cancer by cytotoxic agents can be considered a failure. Since surgery is efficient only in the early forms of disease, other methods of treatment need to be found. Two groups have recently reported that indomethacin, a potent inhibitor of prostaglandin synthesis, was able to inhibit the growth of intestinal tumours indiced by a,variety of carcinogenec agents in the rat (Pollard & Luckert, 1980; Kudo et al., 1980) . It has also been reported that cimetidine, a histamine type-2 receptor antagonist widely used in the treatment of peptic ulcer, could inhibit the growth of experimental tumours in rodents. This could perhaps occur through its blocking effect on histamine H-2 receptors at the surface of suppressor T lymphocytes (Gifford et al., 1981; Osband et al., 1981) .
Because indomethacin and cimetidine could have a cooperative effect on tumour growth, the efficiency of both drugs was tested individually or in combination, on experimental intestinal cancer. Two models were used in this work: a colon carcinoma line transplantable in syngeneic BDIX strain rats and intestinal tunours induced by dimethylhydrazine in Sprague-Dawley rats.
Materials and methods

Animals
Two strains of syngeneic rats were used in this Correspondence: A. Caignard Received 28 March 1984; accepted 16 July 1984. work: BDIX rats, bred in our laboratory by brother-sister mating, and Sprague-Dawley rats (IFFA-Credo, L'Arbresle, France). They were kept in an air-conditioned, humidity-controlled room, with a Light-dark cycle of 12h. They were allowed drinking water ad libidum and fed Extralabo biscuits (Sainte-Colombe, France). To determine the lipidic composition of the biscuits, lipids were extracted according to Folch et al., (1957) and the fatty acids were analyzed by gas-liquid chromatography as their methyl ester derivatives. The mean fatty acid content was 4.3% of the biscuit weight, unsaturated fatty acids and linoleic acid being respectively 60% and 21% of the total fatty acids.
Transplantable colonic tumours Tumour DHD is a transplantable well differentiated carcinoma originating in a colonic tumour induced by 1,2 dimethylhydrazine in a BDIX rat (Martin et al., 1973 Administration of the drugs Indomethacin (Sigma, St Louis, USA) and cimetidine (a gift of Smith, Kline and French, Welwyn Garden, UK) were given in the drinking water at concentrations of 20 mg 1-for indomethacin and 500mgml-1 for cimetidine. We selected the same doses of indomethacin that Pollard & Luckert (1980) had previously used for treating rat colon cancer. The doses of cimetidine were chosen in approximate correspondence to these used by Gifford et al. (1981) 
Results
Transplanted intestinal tumours No significant differences were observed between control and treated animals in terms of tumour incidence, tumour growth rate or tumour weight at the time of sacrifice (Table I) . No metastases were observed in this experiment, probably owing to the short time which elapsed between the tumour graft and the killing of the animals.
Chemically-induced intestinal tumours
Of the 60 DMH-treated animals, only 55 were available for evaluation; 5 rats died in the course of DMH gavage. The rats were sacrificed 7 months after the first administration of DMH except for 4 animals: one was killed on account of a perforation of the small intestine after 10 weeks of treatment by indomethacin and cimetidine, 2 rats were killed after 14 and 17 weeks of treatment with indomethacin respectively for ascites and a tumour of the ear duct, and one rat was killed for jaundice and ascites after 25 weeks of treatment with cimetidine. There was no significant difference in the weight gain of the 4 experimental groups at the time of We found no effect of indomethacin treatment on the growth of a transplanted intestinal carcinoma nor on the incidence of intestinal tumours induced by 1,2 dimethylhydrazine. These negative results confirm our previous results where indomethacin treatment did not modify the growth of tumours induced in the rat by a subcutaneous injection of syngeneic colon cancer cells (Olsson et al., 1984) . These results are contrary to the marked inhibition of chemically-induced rat colon tumours reported by others (Pollard & Luckert, 1980; 1981a, (a) number of rats with metastases to lung or lymph nodes or peritoneal carcinomatosis. 1981b , 1983 Kudo et al., 1980; Narisawa et al., 1981 Narisawa et al., , 1982 . The difference from the results ontained by Pollard & Luckert (1980) in one of their experiments is particularly striking since we used the same strain of rats (Sprague-Dawley), the same process for inducing intestinal tumours with 1-2 dimethylhydrazine and the same treatment by the same dosage of indomethacin in drinking water. In spite of these similarities, two major differences were observed: first, the incidence of intestinal tumours in the control animals was higher in Pollard and Luckert's experiment than in our's (respectively 29 tumour-bearing rats out of 29, with a mean of 3.4 tumours per rat, versus 4 tumourbearing rats out of 13 with a mean of 0.46 tumours per rat). The second was that indomethacin, which significantly decreased the incidence of tumours and the average number of tumours per rat in Pollard and Luckert's experiment, was without effect on these parameters in our experiment. Dietary factors could explain the difference between our results and data reported by other groups. The incidence of intestinal tumours induced in the rat by a variety of carcinogenic drugs increases when animals are given a lipidsupplemented diet (Reddy, 1983) . Unsaturated fatty acids are more efficient than saturated ones, chiefly at low or intermediate concentrations. The same enhancing effect of fatty acids is found for rat mammary tumours, both spontaneous or chemically induced . Carter et al. (1983) have recently shown that indomethacin completely blocked the stimulatory effect of a high-fat diet on mammary tumours induced by diamethylbenzanthracene in Sprague-Dawley rats. Indomethacin had no effect on mammary tumours induced with a low incidence by this agent, in rats fed a low-fat diet. Kollmorgen et al. (1983) have studied the effects of indomethacin on the growth of a mammary tumour transplanted in Wistar-Furth rats fed a semipurified diet containing 2, 5, 10 or 20% corn oil. They found that the rate of tumour growth increased with the dietary oil content in the untreated animals. When the rats received indomethacin in drinking water, at the same concentration (20 mg -1) as in our experiments, the drug did not significantly reduce the slow tumour growth in animals fed a low-fat diet. However, it strongly reduced the growth of tumours transplanted in rats fed high-fat diets. Kollmorgen et al. (1983) also observed that high-fat diets increased the concentration of prostaglandin PGE2 in supernatants of cultured spleen cells from untreated animals. On the contrary, spleen cells of rats treated by indomethacin produced only low amounts of PGE2 whatever the oil content of their diet.
In our experiments, rats were fed a diet containing only 4.3% fatty acids of which 60% were unsaturated. We have no details on the composition of the commercial diets used by Kudo et al. (1980) and Narisawa et al. (1981 Narisawa et al. ( , 1982 in their work on the inhibition of rat colon cancer by indomethacin. Pollard and Luckert fed their rats with a specific diet (Kellog & Wostmann, 1969) which was probably rich in unsaturated fatty acids since it contained 59% ground maize, 30% of soybean oil meal and 3% corn oil. It is possible that qualitative and quantitative differences in dietary fats explain the difference between our results and the data obtained by others in the incidence of chemically-induced tumours and the efficiency of indomethacin treatment in inhibiting these tumours. If the data recently reported by Carter et al. (1983) and Kollmorgen et al. (1983) with the mammary tumour model may be transported to colonic tumours, it might be supposed that indomethacin is only active in animals fed high-fat diets and able to synthesize large amounts of prostaglandins whose inhibitory effects on the immune system are well known (Ceuppens and Goodwin, 1981) . In another study, using the same model, we found that indomethacin was unable to modify tumour cell lysis by activated macrophages from rats fed the same diet (Olsson et al., 1984) . It would be interesting to know if the effects of indomethacin on colon cancer growth in vivo and macrophage-mediated colon cancer cell lysis in vitro are restored in animals fed a high-fat diet.
